Nature of change: Appointment of Chief Investment Officer for wholly-owned subsidiary Gland Pharma International Pte. Ltd (Gland Singapore)
Appointee details: Mr. Xiao Le appointed as Chief Investment Officer
Effective date: November 09, 2026
Reporting structure: Mr. Xiao Le will report to the CEO of Gland Singapore
Professional profile: Mr. Xiao Le has over 15 years of experience in investment and assets management specifically in medical devices, biopharma, diagnostics/tools, and healthcare services sectors
Previous roles: Chief Financial Officer for MegaRobo Technologies (Singapore); Director on Board of CANbridge Pharmaceuticals (United States) representing WuXi; Senior Director of M&A and Strategic Investments for Wuxi AppTec; Director of Dimensions Capital; various roles at Middleton Gardiner Group LLC, NYSE, and Bank of America Merrill Lynch
Geographic experience: Has worked in Singapore, China, and the United States of America
Educational qualifications: Bachelor's degree in Bio-engineering from The Johns Hopkins University; Master's degree in Finance from The Massachusetts Institute of Technology
Responsibilities: Exploring various investment opportunities and improving M&A capability for Gland in the United States of America, China, Singapore and other countries
